Clinical trials: SGLT2 Inhibitor Use
Diabetes Mellitus, Type 2
CGM Use in Adults With Type 2 Diabetes on Basal Insulin
A prospective multi-centre, open-label, two arm, parallel design, superiority, pragmatic, randomised controlled trial, over an 8-month period.
- Trial name
- NCT05944432
- Testing
- FreeStyle Libre 3 Continuous Glucose Monitoring System., Self monitoring of blood glucose
- Where
- 25 sites in United Kingdom
- Volunteers
- 469 people
- Sponsor
- Abbott Diabetes Care
Type 2 Diabetes
Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients
The objective of this survey is to confirm the safety of Suglat Tablets
- Trial name
- STELLALONGTERM (NCT02479399)
- Testing
- ipragliflozin
- Where
- 8 sites in Japan
- Volunteers
- 11,412 people
- Sponsor
- Astellas Pharma Inc
Heart Failure, Heart Failure With Preserved Ejection Fraction (HFPEF)
Sodium-Glucose Cotransporter 2 Inhibitor Use in a National Heart Failure Telemonitoring Program
This observational cohort study evaluates temporal trends and determinants of sodium-glucose cotransporter 2 inhibitor (SGLT2i) prescriptions among adults with chronic heart failure enrolled in a nationwide remote monitoring…
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Reduced Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
- Trial name
- REMOTE-HF (NCT07022379)
- Testing
- SGLT2 Inhibitor Use
- Where
- France
- Volunteers
- 13,660 people
- Sponsor
- Satelia
Type 2 Diabetes
The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes Patients
The objective of this survey is to confirm the safety of Suglat Tablets when used in the elderly.
- Trial name
- STELLA-ELDER (NCT02297620)
- Testing
- Suglat®
- Where
- 8 sites in Japan
- Volunteers
- 8,687 people
- Sponsor
- Astellas Pharma Inc